Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of agomelatine versus paroxetine on quality of remission in elderly depressed patients
2005-002388-95Phase 3Completed
- Sponsor
- Servier
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Quality of remission after 12 weeks of treatment. Started Aug 2005; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-002388-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002388-95.